ข่าวประชาสัมพันธ์ Elacestrant

Menarini Group Presented Initial Safety and Efficacy Data from Phase 1b/2 ELEVATE and ELECTRA Combination Studies of ORSERDU(R) (Elacestrant) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2023 San Antonio Breast Cancer Symposium

ELEVATE and ELECTRA studies were designed with the objective to overcome different treatment resistance mechanisms and enhance patient outcomes with oral-oral combination options. A preliminary analysis of data in the phase 1b part of the ELEVATE trial demonstrates antitumor activity of the combination evaluating ORSERDU with inhibitors of the PI3K/AKT/mTOR pathway and CDK 4/6 inhibitors. Encouraging results from phase 1 ELECTRA, evaluating ORSERDU in combination with abemaciclib regardless of

13 ธันวาคม 2566 08:25 น.

Menarini Group Presents New Progression-Free Survival Data from EMERALD Clinical Study of ORSERDU(R) (Elacestrant) in Clinically Relevant Subgroups of Patients with ER+, HER2- Metastatic Breast Cancer (mBC) with ESR1 Mutations at SABCS 2023

This new post hoc analysis of the Phase 3 EMERALD trial evalu... ธ.ค. 66

Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU(R) (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer

ORSERDU is the first treatment specifically approved for patients with ER+, HER2- advanced or metas... พ.ย. 66

European Commission Approves Menarini Group's ORSERDU(R) (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation

Each year in Europe more than 550,000 patients are diagnosed with breast cancer, of whom 70% have estrogen... ก.ย. 66

Menarini Group Receives Positive CHMP Opinion Recommending EC Approval of ORSERDU(R) (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation

Each year in Europe more than 550,000 patients are diagnosed with breast cancer... ก.ค. 66

Menarini Group Shares New Analysis from EMERALD Clinical Study of ORSERDU(R) (Elacestrant) in Metastatic Breast Cancer at ASCO 2023

ORSERDU (elacestrant) was approved by the FDA in January 2023 for estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or... พ.ค. 66

Menarini Group Announces New Data on Elacestrant at 2023 ESMO Breast Cancer Congress and 2023 ASCO Annual Meeting

The Menarini Group ("Menarini"), a leading Italian pharmaceutical and diagnostics company, and Stemline Therapeutics ("Stemline"), a wholly-owned subsidiary of the Menarini Group,... พ.ค. 66

Carrick Therapeutics and The Menarini Group Announce Clinical Trial Collaboration to Evaluate Samuraciclib and Elacestrant Combination

Carrick to execute Phase 2 clinical trial in patients with CDK4/6i resistant HR+, HER2- metastatic breast cancer Carrick Therapeutics, an oncology-focused... ธ.ค. 65

Menarini Group Presents Updated Results from Pivotal Phase 3 EMERALD Trial at the 2022 San Antonio Breast Cancer Symposium (SABCS) that Demonstrate Elacestrant's PFS Increases with Duration of Prior CDK4/6i in ER+, HER2- in Metastatic Setting

Elacestrant demonstrated longer progression-free survival (... ธ.ค. 65

Menarini Group's Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA) for the Treatment of ER+/HER2- Advanced or Metastatic Breast Cancer

Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available... ส.ค. 65

Menarini Group's Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer

Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from 2L and 3L ER+/HER2- advanced... ส.ค. 65

Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination

Preclinical data support the potential of ONA-XR plus estrogen receptor degraders in endocrine resistant disease models Context to initiate Phase 1b/2... ส.ค. 65

Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant

Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients Priority Review requested; if accepted, anticipate an 8-month FDA review Positive EMERALD study data previously... มิ.ย. 65

Radius Health & Menarini Group Provide Elacestrant Update

- Target enrollment milestone reached in the Phase 3 EMERALD study - Life cycle planning advancing in parallel with current Phase 3 monotherapy program Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) and the Menarini Group today... ก.ย. 63

Menarini Group และ Radius Health บรรลุข้อตกลงอนุญาตใช้สิทธิทั่วโลก เพื่อพัฒนาและจำหน่ายยา Elacestrant

- Menarini คว้าสิทธิในการพัฒนาและจำหน่ายยา Elacestrant ซึ่งเป็นยากลุ่ม SERD ชนิดรับประทานที่อยู่ระหว่างการพัฒนาเฟส 3 ขั้นสุดท้าย - Elacestrant จะเข้ามาเสริมแกร่งกลุ่มผลิตภัณฑ์ยารักษามะเร็งของ... ก.ค. 63

Menarini Group and Radius Health Announce Global License Agreement for the Development and Commercialization of Elacestrant

- Menarini licenses global development and commercialization rights of elacestrant, an oral SERD currently in late stage Phase 3 development - Elacestrant further strengthens... ก.ค. 63